The aim of the current study is to explore the possible role of L55M, (rs 854560, 163T > A) SNP as a predisposing factor for acute coronary syndrome (ACS) and to assess its potency as a prognostic biomarker for short (1 year) survival and for median (5 years) and 9-year long patients’ outcome. Methods: The current work is a prospective case-control study with 77 patients with acute coronary syndrome (53 with ST-elevation myocardial infarction, STEMI, 14 with non-ST-elevation myocardial infarction, NSTEMI and 10 with unstable angina, UA) and 122 control individuals. Patients were followed-up for 9 years. The genotyping for PON1 L55M SNP was carried on by PCR-RFLP method. Results: The results of the genotyping for PON1 L55M SNP showed a statistically significant difference (p = 0.023) between the controls and the whole group of patients with acute coronary syndrome, as the individuals with genotype with at least one variant M allele had about 2.5-fold higher risk for developing ACS than those which are homozygous of the wild-type L allele (LL genotype). In patients with variant M allele genotypes (LM + MM) which suffer from non-ST-segment elevation ACS (NSTEACS, i.e., UA or NSTEMI), the serum levels of total cholesterol (TC) and triacylglycerols (TAG) are significantly higher than in NSTEACS patients with LL genotype (p = 0.022 for TC and p = 0.015 for TAG). There was no significant difference in the survival rate at the 1st, 5th and 9th year of follow-up between ACS patients with different genotypes, although it is worth to note that in the subgroup of NSTEACS, all patients (n = 13) with variant M allele genotypes (LM + MM) were alive at the end of the first year, while 2 of the patients with LL genotype (18.2%) were dead. Conclusions: The results of our current study suggest that the variant M allele and the M allele genotypes (LM + MM) of the PON1 L55M polymorphism are risk factors for acute coronary syndrome, especially for patients with STEMI, but do not support the possible effect of this polymorphism on the clinical progression and outcome of the patients with ACS either in short or long follow-up periods.
COVID-19 is caused by SARS-CoV-2. In March 2020, the WHO declared a pandemic of COVID-19. The virus attacks human angiotensin-converting enzyme 2 receptors (ACE2), which are found in the lungs, vessels, heart, kidneys. This is the cause of the formation of multiple organ dysfunction in severe cases. These ones are observed in patients with accompanying CVD, hypertension, DM, cancer, immune deficiencies. It can lead to hundreds of damage to the cardiovascular system such as myocarditis and CH. Treatment with antiviral medications may cause additional myocardial devices, including rhythm-conduction disorders. The use of ACE inhibitors and ARBs continues according to current guidelines, based on a number of evidence from clinical trials for their use, in the absence of such harm to date in the course of the COVID-19 pandemic.
27 July 2022 in Journal of IMAB – Annual Proceeding (Scientific Papers)
There is an increasing HF population resulting from the higher number of MI survivors and the widespread presence of diabetes, hypertension, CHD (Chronic Heart Filure), obesity and other chronic conditions. Cardiac dysfunction is the main factor that leads to reduced physical activity in patients with HF. The alternations in skeletal musculature often are present in the background of HF and can contribute to fatigue and dyspnea. Sarcopenia is a reduction in muscle mass and force, and it is right to say that it is one of the signs of “getting old”.The modern views on sarcopenia are that it is an outcome of many medical, behavioral and ecological factors, which are common in older people. Together with a sedentary lifestyle, it can be the main reason for disability in the late stages of human life. In our study, we examined the significance of reduced skeletal muscle tissue on mortality and survival of patients with diagnosed HF. The results showed that sarcopenia is a significant contributing factor for increased mortality [p = 0,022] and reduced survival rates [p = 0,033] in patients with HF II – IV class by NYHA. As a secondary goal we found there is significant correlation between age and sarcopenia [R²Linear = 0,057].
3 June 2022 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Background: Infections are common complications among patients on chronic hemodialysis. Catheter-related bloodstream infections (CRBSIs) are estimated to be 0.15 to 3.5 cases per 1000 catheter-days (CD) in case of tunneled catheters, and the frequency of bacterial endocarditis is estimated at 3.5 to 10% of these. Materials and methods: We retrospectively present data from the study, which was conducted in our clinic for a one-year period from January 1 to December 31, 2018. The average number of patients undergoing hemodialysis was 104, and 33 (32%) of them had tunneled catheters. There was 12 045 total CD. We took chemocultures of all patients with clinical signs dubious about CRBSIs. All patients with positive chemocultures were examined by echocardiography. Results: We have found 19 episodes of CRBSIs in 15 patients (1.5/1000 CD). We found a total of 21 causative microbial agents in positive chemocultures, two of which were polymicrobial. Thirteen of the bacteria (62%) were Gram-positive [G (+)] and eight Gram-negative [G (-)] (38%). The most common G (+) bacterium was Staphylococcus aureus 9 and G (-) – Citrobacter coseri. In six patients (32%) with CRBSIs, we found bacterial endocarditis. Four of them (67%) were infected with G (-) negative agent, and two (33%) – with G (+). Conclusions: We conclude that our high incidence of bacterial endocarditis is probably due to the fact that we have examined all of the patients for this complication and that gram-negative bacteria are more often the cause of bacterial endocarditis in patients undergoing hemodialysis with a tunnel catheter.
Introduction: The EVOLUTION-HF is a prospective, multinational, real-world study designed to describe the demographic and clinical characteristics of patients initiating dapaglifl ozin for heart failure with reduced ejection fraction (HFrEF) in nine countries from the Central and Eastern Europe and Baltic Area. This manuscript presents the results of the Bulgarian cohort of the study. Methods: Enrolment period in Bulgaria was between February 2022 and October 2022, in 10 study sites. Demographic and clinical characteristics were collected at baseline (12 months before dapaglifl ozin initiation), and treatment for heart failure (HF), including guideline-directed treatment (GDMT) was collected prospectively until 12 months after dapaglifl ozin initiation. The HF treatment was administered as per routine clinical practice. Results: One hundred and fi fty patients were included in the full analysis set (mean age: 67 years, males 84%). At the time of initiation of dapaglifl ozin 10 mg/day, 69.3% of patients had treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors and 35.3% all four GDMTs in HF. Almost 98% of patients remained on dapaglifl ozin at 6 months and 12 months. Seven (10.12%) dapaglifl ozin discontinuations were recorded throughout the study. The discontinuation rate of dapaglifl ozin was 4.65 per 100 patient-years and the median time-to-discontinuation was not reached. One patient stopped dapaglifl ozin between baseline and 6 month and between 6 month and 12 month-data collection, respectively. GDMT patterns were relatively stable over one year. Conclusion: A high rate of persistence of dapaglifl ozin was observed at 12-month follow-up after initiation for HFrEF. A substantial gap was noted related to GDMT strategy optimization, with only one third of patients receiving all four GDMT pillars. These results obtained in real-world practice in Bulgaria point to the unmet need for targeted efforts to improve GDMT adoption in patients with HFrEF.
14 September 2026 in Journal of IMAB – Annual Proceeding (Scientific Papers)
COVID-19 is associated with a broad spectrum of rhythm and conduction disorders, particularly among hospitalized and critically ill patients. Arrhythmogenesis is multifactorial and reflects systemic inflammation, hypoxaemia, myocardial ischaemia or injury, myocarditis, autonomic imbalance, thromboembolic disease, electrolyte disturbances and drug-related proarrhythmia. Atrial fibrillation is the most frequently reported sustained arrhythmia, while ventricular tachyarrhythmias, bradyarrhythmias and atrioventricular conduction disturbances occur predominantly in patients with severe disease or myocardial injury. Contemporary population-based evidence also indicates that arrhythmic risk may persist beyond the acute infection, although the absolute risk and the contribution of direct viral myocardial injury remain incompletely defined. This review summarizes the principal mechanisms, clinical phenotypes and management considerations of COVID-19-related arrhythmias and highlights emerging evidence concerning post-acute autonomic dysfunction and long-term rhythm complications.